Covagen adds Baxter Ventures as an investor in its Series B financing round raising the total to CHF 44.9 million with an option to extend this to CHF 58.9 Mio. Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The VISCHER team advising Covagen is led by Matthias Staehelin (Corporate) with Marius Meier and Dania Salvisberg.